Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Oslo, Norway, 27 March, 2025 Reference is made to the stock exchange notice published on 26 March 2025 regarding the resolution of the board of directors of Zelluna ASA (the "Company") to carry out a...
-
Oslo, Norway, 26 March, 2025 Reference is made to the stock exchange notice published by Zelluna ASA (the "Company") published on 26 March 2025 regarding the resolution by the Company's board of...
-
Oslo, Norway, 26 March, 2025 Reference is made to the stock exchange notice published on 9 January 2025 regarding an extraordinary general meeting held in Zelluna ASA (the "Company"), where it was...
-
Oslo, Norway, 03 March, 2025 - Zelluna ASA, a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, today announces the...
-
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION...
-
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION...
-
Oslo, January 31, 2025: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its fourth quarter 2024 results...
-
Oslo, January 27, 2025: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, invites to a webcast presentation of its...
-
Oslo, 9 January 2025: Reference is made to the stock exchange notices published by Ultimovacs ASA (the "Company") on (i) 17 December 2024 regarding the contemplated business combination between the...
-
Oslo, January 9, 2025: Ultimovacs ASA held its extraordinary general meeting today January 9, 2025. All the matters on the agenda were approved. The minutes from the meeting are enclosed and...